42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
39 citations,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
38 citations,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
[object Object] 17 citations,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
15 citations,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
14 citations,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
6 citations,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
6 citations,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
4 citations,
April 2023 in “Autoimmunity reviews” High levels of IL6 and CRP, and low levels of vitamin D, might be indicators of alopecia areata.
4 citations,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
4 citations,
April 2019 in “Cell Stem Cell” Certain immune cells in the skin can stop hair from growing.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
December 2024 in “Frontiers in Pharmacology” Araliadiol may promote hair growth like minoxidil without being toxic.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
August 2023 in “Indian journal of pediatrics/Indian Journal of Pediatrics” Topical treatments helped a child with Down syndrome and severe hair loss regrow most of his hair.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
[object Object] Combining epinephrine with a steroid may help regrow hair in severe alopecia areata cases.
June 2024 in “Journal of Allergy and Clinical Immunology” TSLP affects atopic dermatitis by increasing sebum and reducing fat through IL-4/IL-13 signaling.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
September 2024 in “Journal of the American Academy of Dermatology” PRO-C22 can help diagnose and monitor the severity of hidradenitis suppurativa.
147 citations,
November 2020 in “International Journal of Molecular Sciences” Keratinocytes help heal skin wounds by interacting with immune cells and producing substances that kill pathogens.
117 citations,
August 2019 in “Drug Design Development and Therapy” Minoxidil effectively treats hair loss, but use cautiously and monitor side effects.
67 citations,
January 2020 in “Cellular & Molecular Immunology/Cellular & molecular immunology” Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.
61 citations,
January 2019 in “American Journal of Clinical Dermatology” The cause of Frontal Fibrosing Alopecia is unclear, diagnosis involves clinical evaluation and various treatments exist, but their effectiveness is uncertain.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
54 citations,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
47 citations,
December 2020 in “Journal of the European Academy of Dermatology and Venereology” The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.
37 citations,
December 2021 in “Cells” Alopecia areata severity and treatment response are linked to specific cytokine levels.
29 citations,
March 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.